000164856 001__ 164856
000164856 005__ 20230915090558.0
000164856 0247_ $$2doi$$a10.1007/s12035-022-02891-7
000164856 0247_ $$2pmid$$apmid:35716271
000164856 0247_ $$2ISSN$$a0893-7648
000164856 0247_ $$2ISSN$$a1559-1182
000164856 0247_ $$2altmetric$$aaltmetric:129881721
000164856 037__ $$aDZNE-2022-01300
000164856 041__ $$aEnglish
000164856 082__ $$a570
000164856 1001_ $$0P:(DE-2719)9000287$$aSchmitz, Matthias$$b0$$eFirst author$$udzne
000164856 245__ $$aValidation of Plasma and CSF Neurofilament Light Chain as an Early Marker for Sporadic Creutzfeldt-Jakob Disease.
000164856 260__ $$aTotowa, NJ$$bHumana Press$$c2022
000164856 3367_ $$2DRIVER$$aarticle
000164856 3367_ $$2DataCite$$aOutput Types/Journal article
000164856 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1661505075_607
000164856 3367_ $$2BibTeX$$aARTICLE
000164856 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164856 3367_ $$00$$2EndNote$$aJournal Article
000164856 520__ $$aBiomarkers are becoming increasingly important for the differential diagnosis of neurodegenerative diseases. Previous observations indicated neurofilament light chain (NfL) as a potential blood-based biomarker for sporadic Creutzfeldt-Jakob disease (sCJD). Here, we investigated the stability, inter-assay/intra-assay variation and the regulation of NfL levels in CSF and plasma in a large cohort of sCJD patients by using a single-molecule array (SIMOA). We defined cutoffs for an accurate diagnosis and measured plasma NfL level in prion-infected mice models at different time points to identify the potential dynamics throughout the disease. Our analyses confirmed CSF and plasma NfL as stable and consistent marker for sCJD. Receiver operating characteristic (ROC) curve analysis showed an AUC of 0.92-0.93 to distinguish sCJD from control groups. Newly defined cutoffs revealed good diagnostic accuracies of CSF and plasma NfL, indicated by a sensitivity of 80-83.5% and a specificity of 87.4-91%. Studies on two humanized prion-infected mice lines (Tg340-PRNP 129MM and Tg361-PRNP 129VV) revealed increased plasma NfL levels in a late pre-clinical or very early clinical stage between 120-150 days post-inoculation. In conclusion, our work supports the potential use of CSF and plasma NfL as a very early biomarker in sCJD diagnostic with good diagnostic accuracies.
000164856 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000164856 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000164856 650_7 $$2Other$$aBiomarkers
000164856 650_7 $$2Other$$aDiagnostic
000164856 650_7 $$2Other$$aNeurofilament light chain
000164856 650_7 $$2Other$$aPlasma
000164856 650_7 $$2Other$$aSporadic Creutzfeldt-Jakob disease
000164856 650_2 $$2MeSH$$aAnimals
000164856 650_2 $$2MeSH$$aBiomarkers
000164856 650_2 $$2MeSH$$aCreutzfeldt-Jakob Syndrome: diagnosis
000164856 650_2 $$2MeSH$$aHumans
000164856 650_2 $$2MeSH$$aIntermediate Filaments
000164856 650_2 $$2MeSH$$aMice
000164856 650_2 $$2MeSH$$aNeurofilament Proteins
000164856 650_2 $$2MeSH$$aPrions
000164856 650_2 $$2MeSH$$atau Proteins
000164856 7001_ $$0P:(DE-2719)9001944$$aCanaslan, Sezgi$$b1$$eFirst author$$udzne
000164856 7001_ $$aEspinosa, Juan Carlos$$b2
000164856 7001_ $$aFernández-Borges, Natalia$$b3
000164856 7001_ $$0P:(DE-2719)9000327$$aVillar-Piqué, Anna$$b4$$udzne
000164856 7001_ $$0P:(DE-2719)2811280$$aLlorens, Franc$$b5$$udzne
000164856 7001_ $$0P:(DE-2719)9000324$$aVarges, Daniela$$b6$$udzne
000164856 7001_ $$0P:(DE-2719)9001334$$aMaass, Fabian$$b7$$udzne
000164856 7001_ $$aTorres, Juan Maria$$b8
000164856 7001_ $$0P:(DE-2719)2812183$$aHermann, Peter$$b9$$udzne
000164856 7001_ $$0P:(DE-2719)2000058$$aZerr, Inga$$b10$$eLast author$$udzne
000164856 773__ $$0PERI:(DE-600)2079384-4$$a10.1007/s12035-022-02891-7$$n9$$p1-9$$tMolecular neurobiology$$v59$$x0893-7648$$y2022
000164856 909CO $$ooai:pub.dzne.de:164856$$pVDB
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000287$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001944$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000327$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811280$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000164856 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001334$$aExternal Institute$$b7$$kExtern
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812183$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b9$$kDZNE
000164856 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000058$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000164856 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000164856 9141_ $$y2022
000164856 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-30$$wger
000164856 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000164856 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000164856 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000164856 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL NEUROBIOL : 2021$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-22
000164856 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL NEUROBIOL : 2021$$d2022-11-22
000164856 9201_ $$0I:(DE-2719)1440011-1$$kAG Zerr$$lTranslational Studies and Biomarkers$$x0
000164856 9201_ $$0I:(DE-2719)5000037$$kExt UMG Zerr$$lExt UMG Zerr$$x1
000164856 9201_ $$0I:(DE-2719)1440015$$kClinical Dementia Research Göttingen$$lClinical Dementia Research Göttingen$$x2
000164856 980__ $$ajournal
000164856 980__ $$aVDB
000164856 980__ $$aI:(DE-2719)1440011-1
000164856 980__ $$aI:(DE-2719)5000037
000164856 980__ $$aI:(DE-2719)1440015
000164856 980__ $$aUNRESTRICTED